Tretinoin and cutaneous photoageing: new preparation. Guaranteed adverse effects!
(1) A cream containing 0.05% of tretinoin is approved in France for the treatment of sun-induced skin damage ("photoageing").  (2) Three comparative trials versus the excipient show that the effects of the tretinoin cream are at best limited and slow to occur; furthermore, they disappear on treatment cessation, necessitating long-term use.  (3) The 0.05% tretinoin cream has poor local tolerability: most subjects develop irritation and fragile skin, necessitating a longer interval between each application.  Systemic adverse effects can occur in some circumstances.  (4) There are persistent doubts over safety during pregnancy.
D002986:Clinical Trials as Topic; D000075202:Contraindications; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007641:Keratolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D015595:Skin Aging / Q000187:drug effects; D016896:Treatment Outcome; D014212:Tretinoin / Q000009:adverse effects / Q000627:therapeutic use
D007641:Keratolytic Agents; D014212:Tretinoin